Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Pharmacological treatment of dementia.

Schwarz S, Froelich L, Burns A.

Curr Opin Psychiatry. 2012 Nov;25(6):542-50. doi: 10.1097/YCO.0b013e328358e4f2. Review.

PMID:
22992546
2.

Treatment of dementia: anything new?

Machado JC, Caramelli P.

Curr Opin Psychiatry. 2006 Nov;19(6):575-80. Review.

PMID:
17012934
3.

Use of memantine for the treatment of dementia.

Lo D, Grossberg GT.

Expert Rev Neurother. 2011 Oct;11(10):1359-70. doi: 10.1586/ern.11.132. Review.

PMID:
21955192
4.

Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.

Popp J, Arlt S.

Curr Opin Psychiatry. 2011 Nov;24(6):556-61. doi: 10.1097/YCO.0b013e32834b7b96. Review.

PMID:
21934621
5.
6.

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.

Burns A, O'Brien J; BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology.

J Psychopharmacol. 2006 Nov;20(6):732-55. Review.

PMID:
17060346
7.

Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.

Thomas SJ, Grossberg GT.

Clin Interv Aging. 2009;4:367-77. Epub 2009 Oct 12. Review.

8.

The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.

Miller LJ.

Consult Pharm. 2007 Sep;22(9):754-62. Review.

PMID:
18198970
9.

Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.

Kerchner GA, Tartaglia MC, Boxer A.

Expert Rev Neurother. 2011 May;11(5):709-17. doi: 10.1586/ern.11.6. Review.

10.

Behavioral effects of current Alzheimer's disease treatments: a descriptive review.

Cummings JL, Mackell J, Kaufer D.

Alzheimers Dement. 2008 Jan;4(1):49-60. doi: 10.1016/j.jalz.2007.10.011. Review.

PMID:
18631950
11.

Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.

Ballard C, Corbett A, Chitramohan R, Aarsland D.

Curr Opin Psychiatry. 2009 Nov;22(6):532-40. doi: 10.1097/YCO.0b013e32833111f9. Review.

PMID:
19696673
12.
13.

[Pharmacological treatment of behavioral symptoms in dementia patients].

Gabryelewicz T.

Przegl Lek. 2014;71(4):215-20. Review. Polish.

PMID:
25141581
14.

Current and emerging pharmacological treatment options for dementia.

Ringman JM, Cummings JL.

Behav Neurol. 2006;17(1):5-16. Review.

PMID:
16720956
15.

Alzheimer's disease: early diagnosis and treatment.

Chu LW.

Hong Kong Med J. 2012 Jun;18(3):228-37. Review.

16.

Memantine: a review of its use in Alzheimer's disease.

Robinson DM, Keating GM.

Drugs. 2006;66(11):1515-34. Review.

PMID:
16906789
17.

[Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia--common features and differences].

Drach LM.

Med Monatsschr Pharm. 2011 Feb;34(2):47-52; quiz 53-4. Review. German.

PMID:
21428015
18.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191. Review.

19.
20.

Current issues in dementia pharmacotherapy.

Daiello LA.

Am J Manag Care. 2007 Dec;13 Suppl 8:S198-202. Review.

Items per page

Supplemental Content

Write to the Help Desk